UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Network meta‐analysis of post‐exposure prophylaxis randomized clinical trials

Fernández, I; De Lazzari, E; Inciarte, A; Diaz-Brito, V; Milinkovic, A; Arenas-Pinto, A; Etcheverrry, F; ... Gatell, JM; + view all (2021) Network meta‐analysis of post‐exposure prophylaxis randomized clinical trials. HIV Medicine , 22 (3) pp. 218-224. 10.1111/hiv.12964. Green open access

[thumbnail of Arenas-Pinto_Metanalisis PEPshort.pdf]
Preview
Text
Arenas-Pinto_Metanalisis PEPshort.pdf - Accepted Version

Download (989kB) | Preview

Abstract

Objectives: We performed a network meta‐analysis of PEP randomized clinical trials to evaluate the best regimen. / Methods: After MEDLINE/Pubmed search, studies were included if: (1) were randomized, (2) comparing at least 2 PEP three‐drug regimens and, (3) reported completion rates or discontinuation at 28 days. Five studies with 1105 PEP initiations were included and compared ritonavir‐boosted lopinavir (LPV/r) vs. atazanavir (ATV) (one study), cobicistat‐boosted elvitegravir (EVG/c) (one study), raltegravir (RAL) (one study) or maraviroc (MVC) (two studies). We estimated the probability of each treatment of being the best based on the evaluation of five outcomes: PEP non‐completion at day 28, PEP discontinuation due to adverse events, PEP switching due to any cause, lost to follow‐up and adverse events. / Results: Participants were mostly men who have sex with men (n = 832, 75%) with non‐occupational exposure to HIV (89.86%). Four‐hundred fifty‐four (41%) participants failed to complete their PEP course for any reason. The Odds Ratio (OR) for PEP non‐completion at day 28 in each antiretroviral compared to LPV/r was: ATV 0.95 (95% CI 0.58–1.56; EVG/c: OR 0.65 95% CI 0.30–1.37; RAL: OR 0.68 95% CI 0.41–1.13; and MVC: OR 0.69 95% CI 0.47–1.01. In addition, the rankogram showed that EVG/c had the highest probability of being the best treatment for the lowest rates in PEP non‐completion at day 28, switching, lost to follow‐up or adverse events and MVC for PEP discontinuations due to adverse events. / Conclusions: Our study shows the advantages of integrase inhibitors when used as PEP, particularly EVG as a Single‐Tablet Regimen.

Type: Article
Title: Network meta‐analysis of post‐exposure prophylaxis randomized clinical trials
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/hiv.12964
Publisher version: https://doi.org/10.1111/hiv.12964
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: completion, HIV, integrase inhibitors, post‐exposure prophylaxis
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health
URI: https://discovery.ucl.ac.uk/id/eprint/10115427
Downloads since deposit
184Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item